Celcuity Reports Second Quarter 2020 Financial Results and Recent Business Highlights

dnrt8765

– Presented data for first CELsignia Pathway Activity Test for ovarian cancer at AACR Annual Meeting –

– Expect to announce new clinical trial collaborations with pharmaceutical companies and trial sponsors by the end of 2020 –

– Cash burn rate steady –

– Cash and Cash Equivalents of $15.4 million as of June 30, 2020, which is expected to support operations through 2021 –

– Conference Call on Monday, August 10th at 4:30pm (ET) –

MINNEAPOLIS, MN / ACCESSWIRE / August 10, 2020 / Celcuity Inc. (NASDAQ:CELC), a clinical stage biotechnology company translating discoveries of new cancer sub-types into

Mannatech Reports Second Quarter 2020 Financial Results

dnrt8765

Mannatech, Incorporated (NASDAQ: MTEX), a global health and wellness company committed to transforming lives to make a better world, today announced financial results for its second quarter of 2020.

Second Quarter End Results

Second quarter net sales for 2020 were $37.6 million, a decrease of $3.1 million, or 7.5%, as compared to $40.7 million in the second quarter of 2019. Income from operations decreased to $1.1 million for the second quarter of 2020, from $2.0 million in the same period in 2019.

Net income was $1.1 million, or $0.47 per diluted share, for the second quarter of 2020, as compared

Biohaven Reports Second Quarter 2020 Financial Results And Recent Business Developments

dnrt8765

– NURTEC™ ODT (rimegepant) achieved net revenues of $9.7M for the second quarter of 2020 and now NBRx market leader with 52.6% of share

– Company well-capitalized with recent non-dilutive financing of up to $950M from Sixth Street term loan and Royalty Pharma funding agreement

– Remains on timelines for NURTEC ODT sNDA filing for prevention of migraine in the coming months; additionally, completion of troriluzole Alzheimer’s Disease Phase 2/3 trial in 4Q2020, and topline results with troriluzole in Alzheimer’s Disease and Spinocerebellar Ataxia, and verdiperstat in Multiple System Atrophy in 2021

NEW HAVEN, Conn., Aug. 10, 2020 /PRNewswire/

Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates

dnrt8765

– First patient dosed with STK-001 in Part A of Phase 1/2a MONARCH clinical trial for Dravet syndrome –

– Company on track to identify an additional pre-clinical candidate derived from its TANGO platform for the treatment of an additional genetic disease in 2H 2020 –

– As of June 30, 2020, company has $202.1 million in cash, cash equivalents and restricted cash, anticipated to fund operations into 2023 –

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today reported financial results for